<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3248">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322396</url>
  </required_header>
  <id_info>
    <org_study_id>KronLungesyg_COVID_19_protokol</org_study_id>
    <nct_id>NCT04322396</nct_id>
  </id_info>
  <brief_title>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</brief_title>
  <acronym>ProPAC-COVID</acronym>
  <official_title>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chronic Obstructive Pulmonary Disease Trial Network, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chronic Obstructive Pulmonary Disease Trial Network, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores whether patients acutely hospitalized may have shorter hospitalization
      and fewer admittances at Intensive Care Units by treatment with azithromycin and
      hydroxychloroquine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the ongoing coronavirus pandemic, COVID-19, that arose in Wuhan China, there is still
      sparse data in the course, risk of various complications, and in particular how patients who
      are hospitalized are best treated to ensure high survival and short hospitalization. Despite
      the rapid spread of the disease globally, there is no solid data yet to recommend any
      specific treatments, which is why symptomatic, organ supportive therapy including respiratory
      therapy in acute pulmonary failure is recommended. There has been reported a high incidence
      of bacterial super-infections in patients with COVID-19. Patients with COVID-19 also have a
      higher risk of dying because of septic shock. Thus, there is an urgent need for treatment
      that can improve the patient's chance of the shortest hospitalization possible, and treatment
      that can lower the risk of secondary infection and death.

      This is a randomized, placebo-controlled, double-blinded multi-center trial evaluating the
      effect of azithromycin and hydroxychloroquine treatment in patients with COVID-19 during
      hospitalization. The aim of the study is to investigate whether the treatment can shorten
      hospitalization, reduce the risk of non-invasive ventilation, admittance to Intensive Care
      Units and death.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days alive and discharged from hospital within 14 days</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Categorization of hospitalization status</measure>
    <time_frame>14 days</time_frame>
    <description>The patient will becategorized into one of the following 8 categories depending on status of their hospitalization:
Dead (yes/no)
Hospitalized and receiving mechanical ventilation or ExtraCorporalMembraneOxygenation (ECMO) (yes/no)
Hospitalized and receiving Non-invasive ventilation or &quot;high-flow oxygen device&quot; (yes/no)
Hospitalized and given oxygen supplements different from (2) and (3) (yes/no)
Hospitalized and without oxygen treatment, but receiving other treatment (both related to COVID-19 or other) (yes/no)
Hospitalized for observation (yes/no)
Discharged from hospital with restriction of activity level (yes/no)
Discharged from hospital without any restrictions of activity level (yes/no)
Only one category can be &quot;yes&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admitted to intensive care unit, if admitted to ICU then length of stay</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Have used Non-invasive ventilation (NIV) during hospitalization</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and discharged from hospital</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of readmissions (all causes)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days using non-invasive ventilation (NIV)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient's oxygen partial pressure</measure>
    <time_frame>4 days</time_frame>
    <description>Delta PaO2 measured in arterial puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient's carbondioxid partial pressure</measure>
    <time_frame>4 days</time_frame>
    <description>Delta PaCO2 measured in arterial puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of pH in blood</measure>
    <time_frame>4 days</time_frame>
    <description>pH measured in arterial puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for no oxygen supplement (or regular oxygen supplement &quot;LTOT&quot;)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Virus Diseases</condition>
  <condition>Infection Viral</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will receive standard care and placebo in 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo Azithromycin</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo Hydroxychloroquine</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient admitted to a Danish emergency department, lung medical department or medical
             department

          -  Age &gt;18 years

          -  Hospitalized &lt;48 hours

          -  Positive COVID-19 test/diagnosis during the hospitalization

          -  Signes informed consent

        Exclusion Criteria:

          -  If the patient uses &gt; 5 LO2/min at time of recruitment

          -  Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to
             quinine or 4-aminoquinolinderivates

          -  Pregnancy

          -  Breatfeeding

          -  Neurogenic hearing loss

          -  Psoriasis

          -  Retinopathy

          -  Maculopathy

          -  Changes in vision field

          -  Severe liver disease other than amoebiases

          -  Severe gastrointestinal, neurological or haematological disorders

          -  eGFR &lt; 45 ml/min/1.73m2

          -  Clinically significant cardiac conduction disorders/arrhytmias or prolonged QTc
             interval

          -  Myasthenia Gravis

          -  Uses Digoxin

          -  Glucose-6-phosphate dehydrogenase defiency

          -  Porphyria

          -  Hypoglycemia at any time since hospitalization

          -  Severe mental illness which significantly impedes cooperation

          -  Severe linguistic problems that significantly impedes cooperation

          -  Treatment with sickle alkaloids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jens-Ulrik Stæhr Jensen, MD, PhD</last_name>
    <phone>004528938168</phone>
    <email>jens.ulrik.jensen@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg Sygehus</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulla Weinreich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Therese Lapperre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev-Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens-Ulrik Jensen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Ulrik</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Browatzki</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Laursen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roskilde Sygehus</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Meyer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Slagelse Sygehus</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uffe Bødtger</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

